Anemia is a common feature of multiple myeloma. Its causation is multifactorial, but some patients benefit from recombinant human erythropoietin (rHuEpo).
The Role of rHuEpo
Following the molecular cloning of erythropoietin in 1985, rHuEpo was first found to be effective in the treatment of anemia associated with renal failure. 6 In a study of patients with myeloma receiving hemodialysis, rHuEpo appeared to be effective in treating anemia, but the required doses appeared higher compared with those of patients with other causes of renal failure. 7 This finding suggested that in addition to reduced serum erythropoietin levels found in myeloma patients, the marrow response to rHuEpo may be attenuated in myeloma patients compared with other patients with anemia. The distinction between deficient erythropoietin levels and marrow unresponsiveness may be important in the treatment of anemia of myeloma. Presumably, replacement doses of rHuEpo may be sufficient to induce a response in patients with low serum erythropoietin levels, but higher doses may be necessary in patients with a blunted marrow response.
In 1990, Ludwig et al 8 first reported results using rHuEpo for treatment of anemia associated with multiple myeloma. Treatment with incremental doses of rHuEpo starting at 150 U/kg three times per week for six months resulted in an improvement in 11 of 13 patients. Increases in hemoglobin were associated with a significant improvements in quality of life and sense of well being. In a similar phase II trial, Barlogie and Beck 9,10 reported their experience in treating patients with 150 U/kg three times per week and observed a response rate of 78%. These investigators also found that pretreatment serum erythropoietin levels greater than 100 U predicted a lack of response to exogenous rHuEpo.
Recently, two prospective, randomized, controlled trials using rHuEpo have been reported for the treatment of the anemia of multiple myeloma. 11, 12 A study by Garton et al 11 reported the results of a single institution study comparing placebo to 150 U/kg rHuEpo administered subcutaneously three times per week for six weeks. Of the 10 patients receiving rHuEpo, six had a complete response (defined as a final hematocrit of 0.38 or greater without transfusions), one patient had a partial response, and three were nonresponders. No responses were seen in the placebo arm. Of the 10 patients who originally received placebo, three had a complete response when crossed over to the treatment arm, and one patient had a partial response. In terms of dose of rHuEpo required to achieve a response, both partial responders required higher doses of 300 U/kg three times per week. Of the nine complete responders, seven required the dose of 300 U/kg, and two achieved responses at the 150 U/kg dose. In this study, pretreatment erythropoietin levels did not predict for response to rHuEpo. Although this study involved few patients, the investigators recommended that pretreatment erythropoietin levels were not necessary and that all myeloma patients with anemia should be treated with an initial dose of 150 U/kg three times per week. The necessity of increasing the dose to 300 U/kg could not be addressed by this study, but presumably if no response is seen after six weeks of 150 U/kg, the dose should be increased to 300 U/kg three times per week.
In 1995, Cazzola et al 12 reported the results of a randomized, controlled, multicenter study conducted in Europe in which 146 patients were randomized to either placebo or four different dosages of rHuEpo. Eighty-four patients had multiple myeloma, and 62 had non-Hodgkin's lymphoma. A daily dose of 1,000 U did not show any effect in improving anemia, whereas a clear dose-dependent improvement was observed in the doses ranging from 2,000 to 10,000 U per day. A response was defined as an increase in hemoglobin level of at least 2 g/dL between baseline and two consecutive measurements following treatment. Maximum responses appeared to occur by eight weeks of therapy, and there was no substantial difference between the 1,000 and 10,000 U daily doses. Importantly, using a regression analysis and classification and regression tree analysis, these investigators found that pretreatment serum erythropoietin levels and the observed/ predicted (O/P) ratio for serum erythropoietin were the best prognostic factors for predicting a response to rHuEpo. The best discriminating cutoff points for predicting response to rHuEpo were a serum level of 50 U/mL or an O/P ratio of 0.8 with 80% of patients responding to rHuEpo within eight weeks of therapy if levels were below the cutoff points. In contrast, the response rates were between 20% and 30% for patients with pretreatment values above the cutoff points. These investigators concluded that the decision to use rHuEpo in a patient with anemia associated with myeloma should be based on pretreatment serum levels.
Essentially all studies have shown that rHuEpo is effective and safe in patients with anemia associated with myeloma. Response rates range from 55% to 85%, and its use reduces the need for multiple blood transfusions. Patients who respond have improved quality of life and are not exposed to the risks associated with repeated blood transfusions. The drug appears safe, and hypertension or hyperviscosity syndromes have not been a significant problem. Questions remain, however, regarding which patients to treat. For example, should all patients with anemia be treated or only those with a lower-than-predicted serum erythropoietin level? Issues regarding when to stop the drug because of lack of response vs increasing the dose also are unresolved.
Suggested Guidelines for the Use of rHuEpo in the Treatment of Anemia Associated With Myeloma
Which patients with multiple myeloma should receive rHuEpo? Patients who have a hemoglobin level of less than 11 g/dL may benefit from the use of rHuEpo. Waiting until the patient becomes overtly symptomatic from anemia is not advised. Patients who are symptomatic from anemia may need blood transfusions before beginning rHuEpo. As stated in the study by Garton et al, 11 newly diagnosed myeloma patients who have anemia as the only manifestation of their disease (ie, have no lytic bony disease) may benefit from rHuEpo as the sole initial treatment of their disease. In this subset of patients, anemia represents the only symptomatic problem, and correction of the problem with rHuEpo may delay the need for chemotherapy until the disease progresses. In contrast to this situation, patients with more advanced disease may have improvement in their anemia when treated with chemotherapy. Patients whose hemoglobin levels remain below 11 g/dL despite chemotherapy may benefit from the use of rHuEpo. A baseline serum erythropoietin level should be obtained before beginning rHuEpo. Although no data are available from the current clinical trials, patients with normal serum erythropoietin levels may need a higher dose of rHuEpo to obtain a response compared to patients with low levels of serum erythropoietin.
What dose of rHuEpo should be used? Most studies have demonstrated that a starting dose of 150 U/kg given subcutaneously three times per week is a sufficient starting dose. For those patients who respond to rHuEpo, benefit usually is seen by eight weeks of therapy. (A complete response is defined as a hemoglobin level of 13 g/dL or greater, and a partial response is an incremental increase of > or = 2 g/dL.) If a response is not seen by eight weeks, then the dose may be increased to 300 U/kg three times weekly for one month. As mentioned above, higher doses of rHuEpo may be required for patients with normal or high baseline levels of serum erythropoietin. If no response is seen following four additional weeks of an increased rHuEpo dose, a response is unlikely and the drug should be discontinued.
What is the role of maintenance rHuEpo therapy following a response? Once a satisfactory response has been obtained with rHuEpo, the dose should be reduced by half to try to maintain the response. In some cases, the rHuEpo may be discontinued, but careful observation is necessary to ensure that the patient does not develop recurrent anemia.
What side effects can be anticipated? Generally, rHuEpo is well tolerated when administered subcutaneously at a dose of 150 U/kg three times weekly. Potential side effects in the myeloma patient include hypertension and hyperviscosity syndrome; however, these are uncommon and should be treated in the usual fashion.
